Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 1
1(33.3%)
3Total
N/A(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06999408Not ApplicableActive Not Recruiting

Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning

Role: lead

NCT03956797Not ApplicableCompleted

Long Term Safety of Cooling Anesthesia for Intravitreal Injection

Role: lead

NCT03732287Phase 1Completed

Cooling Anesthesia for Intravitreal Injection

Role: lead

All 3 trials loaded